Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Mesiano

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Expert Opinion on Biological Therapy|April 17, 2012
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumorsGiulia Mesiano, Maja Todorovic, Loretta Gammaitoni, et al.
Journal of Translational Medicine|August 31, 2018
Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identitySara Castiglia, Aloe Adamini, Deborah Rustichelli, et al.
Expert Opinion on Biological Therapy|December 18, 2014
Adoptive immunotherapy against sarcomasGiulia Mesiano, Valeria Leuci, Lidia Giraudo, et al.
Cells|November 27, 2021
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and ChondrosarcomaGiorgia Giordano, Alessandra Merlini, Giulio Ferrero, et al.
Molecular Medicine (Cambridge, Mass.)|August 15, 2017
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer CellsGiulia Mesiano, Roberta Zini, Giulia Montagner, et al.
Journal of Biotechnology|September 22, 2011
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectorsValeria Leuci, Giulia Mesiano, Loretta Gammaitoni, et al.
Oncoimmunology|November 6, 2018
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapyGiulia Mesiano, Giovanni Grignani, Erika Fiorino, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 16, 2012
Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriersMaja Todorovic, Giulia Mesiano, Loretta Gammaitoni, et al.
Cancer Immunology, Immunotherapy : CII|September 23, 2025
The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytesGiorgia Giordano, Alessandra Merlini, Federica Capozzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2013
Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness featuresLoretta Gammaitoni, Lidia Giraudo, Valeria Leuci, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Expert Opinion on Biological Therapy|April 17, 2012
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumorsGiulia Mesiano, Maja Todorovic, Loretta Gammaitoni, et al.
Journal of Translational Medicine|August 31, 2018
Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identitySara Castiglia, Aloe Adamini, Deborah Rustichelli, et al.
Expert Opinion on Biological Therapy|December 18, 2014
Adoptive immunotherapy against sarcomasGiulia Mesiano, Valeria Leuci, Lidia Giraudo, et al.
Cells|November 27, 2021
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and ChondrosarcomaGiorgia Giordano, Alessandra Merlini, Giulio Ferrero, et al.
Molecular Medicine (Cambridge, Mass.)|August 15, 2017
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer CellsGiulia Mesiano, Roberta Zini, Giulia Montagner, et al.
Journal of Biotechnology|September 22, 2011
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectorsValeria Leuci, Giulia Mesiano, Loretta Gammaitoni, et al.
Oncoimmunology|November 6, 2018
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapyGiulia Mesiano, Giovanni Grignani, Erika Fiorino, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 16, 2012
Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriersMaja Todorovic, Giulia Mesiano, Loretta Gammaitoni, et al.
Cancer Immunology, Immunotherapy : CII|September 23, 2025
The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytesGiorgia Giordano, Alessandra Merlini, Federica Capozzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2013
Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness featuresLoretta Gammaitoni, Lidia Giraudo, Valeria Leuci, et al.
Pageof 3